We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

DIASYS DIAGNOSTIC SYSTEMS

  Gold Develops, manufactures, and distributes diagnostic systems for clinical chemistry and immunoturbidimetry. Supplies hi... read more Featured Products: More products

Download Mobile App





Diasys Launches New SARS-CoV-2 UTAB FS Universally Applicable Total Antibody Test

By LabMedica International staff writers
Posted on 02 Mar 2021
Print article
Illustration
Illustration
DiaSys Diagnostic Systems GmbH (Holzheim, Germany) has launched a new immunoturbidimetric test for the quantitative determination of total antibodies in COVID-19.

The universally applicable total antibody test, called SARS-CoV-2 UTAB FS (UTAB = Universal Total AntiBody), allows to detect whether a person has already been infected with SARS CoV-2 and may have developed immunity to the corona virus. The test detects antibodies of the early immune response (IgM and IgA antibodies) as well as antibodies that evoke a more long-lasting specific immune response in blood (antibody class IgG). The SARS-CoV-2 UTAB FS test for clinical diagnostic laboratories provides reliable and indicative results for patient management within only 10 minutes. The test requires no special equipment and allows comparable results on nearly all clinical chemistry analyzers available worldwide.

It is scientifically proven that the virus attaches to the host cell via a special binding site in the spike 1 envelope protein, the so-called receptor binding domain, or RBD for short, and then infects the host cell. Antibodies against this RBD are able to suppress the attachment of the virus to the host cell and thus its infection and are consequently called neutralizing antibodies. Due to the importance of these antibodies, DiaSys has selected the RBD as the target antigen for the assay to determine total antibodies in COVID-19.

Quantitative assessment of antibodies against the RBD domain of the spike protein, so-called anti-RBD SARS-CoV-2 antibodies, is becoming increasingly important. It provides information on the actual spread of infection in the population and enables characterization of a vaccine-induced immune response. It allows to define the initial antibody status, captures the change in antibody levels induced by a vaccine, and permits to judge the efficacy of a vaccine and to determine required vaccination intervals.


Gold Supplier
SARS-CoV-2 Assay
SARS-CoV-2 Total (COV2T) Assay
New
COVID-19 ELISA Test
Kantaro COVID-SeroKlir
New
Molecular Diagnostics Integrated System
SENTiNAT 200
New
SARS-CoV-2 RUO Solution
QuantiFERON SARS-CoV-2 RUO

Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: The EZ DNA Methylation-Direct Kit (Photo courtesy of Zymo Research)

Leukocyte Epigenomics and Artificial Intelligence Predict Late-Onset Alzheimer’s Disease

Alzheimer’s Disease (AD) is the most common form of age-related dementia, accounting for 60%–80% of such cases. The disorder causes a wide range of significant mental and physical disabilities, with profound... Read more

Industry

view channel
Image: The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing (Photo courtesy of Mobidiag Ltd.)

Hologic to Acquire Mobidiag to Strengthen Diagnostic Testing Business

Hologic, Inc. (Marlborough, MA, USA) has signed a definitive agreement to acquire Mobidiag Ltd. (Espoo, Finland) in a USD 795 million transaction that will accelerate the global growth of Mobidiag’s differentiated... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.